 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Digilab BioVisioN GmbH
|
-
Digilab BioVisioN receives ISO 9001:2000 Certificate
(08 Aug 2007)
Digilab BioVisioN GmbH announced it has received ISO 9001:2000 certification by the TÜV Rheinland. The certification comprises Digilab BioVisioN's business of offering research collaborations and services. These collaborations and services encompass ...
-
Digilab Peptidomics receives United States Patent for Alzheimer's Disease Biomarkers
(12 Jul 2007)
Digilab Peptidomics®, formerly BioVisioN, was granted a patent by the US Patent Office for a new panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases. Using proprietary Peptidomics®-Technologies, scientists ...
-
Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim
(06 Apr 2006)
Digilab BioVisioN GmbH announced closing of a cooperation contract with Boehringer Ingelheim Pharma GmbH & Co. KG. This is the first collaboration contract of the company that takes over commercial activities from BioVisioN AG within a ...
-
BioVisioN receives research grant within BioChancePLUS program
(08 Aug 2005)
BioVisioN AG announced the receipt of approval of a research grant within the German BioChancePLUS program. The German Federal Ministry of Education and Research (BMBF) will fund the Project on "Functional Peptidomics" that aims at the ...
-
BioVisioN AG sells its subsidiary ImVisioN GmbH to Nextech Venture, L.P.
(10 May 2005)
German biotech company BioVisioN AG has sold its spin-off, ImVisioN GmbH, to the Swiss based life science investment firm Nextech Venture, L.P.ImVisioN focuses on the development of novel immunotherapeutics based on its proprietary MAT ...
-
BioVisioN AG receives United States Patent for Peptide-Biomarker Discovery and Identification Technology
(12 Apr 2005)
The patent office of the United States of America has granted the patent for BioVisioN's core technology, the "Differential Peptide Display"® (DPD), for the discovery and identification of peptide biomarkers. The methods allow the analysis and ...
-
ImVisioN GmbH - BioVisioN spins off new enterprise with peptide vaccine portfolio
(13 Dec 2004)
BioVisioN announces the spin-off of a drug portfolio for causative treatment of allergic diseases - This drug portfolio may lead the way to a new concept for vaccination applicable also to other indications. Today the CEO of the Hannover, Germany ...
-
Cooperation between BioVisioN and Roche Diagnostics
(28 May 2003)
Roche Diagnostics is validating new marker candidates for diagnosis of Alzheimer Disease
Since entering into a cooperation project with Roche Diagnostics GmbH of Mannheim in 1999, Hanover-based biotechnology firm BioVisioN has identified a number of proteins that may enable early diagnosis of Alzheimer's Disease and distinguish it from ...
Additional information
Digilab BioVisioN GmbH
Hannover, Germany
Company
Products
|
|
|
|
|
|
Top
